Do you feel your memory isn't what it used to be? Do you or a loved on have a diagnosis of Mild Cognitive Impairment (MCI) or dementia due to the early stages of Alzheimer's disease (AD)?
The Mission AD study is assessing the effectiveness and safety of an investigational medication (a "BACE" inhibitor, which stops the formation of the building blocks of amyloid in the brain) to improve the symptoms of Alzheimer's disease. The sponsor of this study is Eisai pharmaceutical company.
You may be eligible for the Mission AD study if you:
- Are age 50 to 85
- Have noticeable changes in your memory of thinking abilities that might be related to Mild Cognitive Impairment (MCI) or mild dementia due to early Alzheimer's disease (AD)
- Have a study partner who knows you well and can attend certain visits with you and tell us about your health and well-being
If you are interested and would like more information, please contact Leah Levine, (617) 525-3167.